Referência de medicamentos
Zenocutuzumab
Zenocutuzumab is a medicine in the class oncology. It is used for non-small cell lung cancer.
- Classe do medicamento: Oncology
- Indicado para: non-small cell lung cancer
Última atualização Fontes: US FDA label
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Pontos-chave
- Classe do medicamento
- Oncology
- Formas farmacêuticas comuns
- injeção
- Concentrações comuns
- 20 mg/ml
- Nomes comerciais
- 1
- Países e mercados
- 1
Para que é usado
Como funciona
Bispecific antibody that binds the extracellular domains of HER2 and HER3, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3. It decreases cell proliferation and PI3K-AKT-mTOR signaling, and mediates antibody-dependent cellular cytotoxicity.
Dose habitual em adultos (resumo da bula)
NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma or cholangiocarcinoma: 750 mg IV infusion over 4 hours every 2 weeks until disease progression or unacceptable toxicity
Gravidez e amamentação
- Gravidez
- Unsafe Can cause fetal harm: HER2/HER3 loss causes malformations and embryo death in animals, and HER2 antibodies have caused low amniotic fluid. Avoid; check pregnancy status and use contraception during and for 2 months after the last dose. If exposed, monitor amniotic fluid.
- Amamentação
- Unsafe No milk data; as an IgG1 antibody little is expected in milk and it is probably digested. US label: weigh benefits, allowing for the 2-month washout. LactMed: manufacturer advises no breastfeeding during treatment and for 2 months after. Do not breastfeed until 2 months after.
Efeitos adversos relatados
- Diarrhea
- Musculoskeletal pain
- Fatigue
- Nausea
- Infusion-related reactions
- Dyspnea
Advertências de caixa preta
- Embryo-fetal toxicity: exposure during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception.
Quem deve ter cuidado
- Serious and life-threatening infusion-related reactions, hypersensitivity and anaphylaxis can occur. Give in a setting with emergency resuscitation equipment and monitor during and for at least 1 hour after the first infusion.
- Serious and life-threatening ILD/pneumonitis can occur. Monitor for new or worsening pulmonary symptoms.
- Left ventricular dysfunction can occur. Evaluate LVEF before starting and monitor at regular intervals. It has not been studied in patients with LVEF below 50% or clinically significant cardiac disease.
Informe ao farmacêutico ou ao médico sobre gravidez ou amamentação, doença renal ou hepática, alergias e todos os outros medicamentos ou suplementos que você usa.
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para abrir a monografia completa de Zenocutuzumab: doses, gravidez e amamentação, efeitos adversos, advertências e todas as interações.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
Experimente o Pro+ grátis por 7 dias na web. Sem cartão.
Outros medicamentos desta classe
Perguntas frequentes
What is Zenocutuzumab used for?
Zenocutuzumab is a medicine in the class oncology. It is used for Non-small cell lung cancer, Pancreatic cancer.
What side effects have been reported with Zenocutuzumab?
Diarrhea, Musculoskeletal pain, Fatigue, Nausea, Infusion-related reactions, Dyspnea. Serious warning: Embryo-fetal toxicity: exposure during pregnancy can cause embryo-fetal harm.
Can Zenocutuzumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: HER2/HER3 loss causes malformations and embryo death in animals, and HER2 antibodies have caused low amniotic fluid. Avoid; check pregnancy status and use contraception during and for 2 months after the last dose. If exposed, monitor amniotic fluid. Breastfeeding: Unsafe. No milk data; as an IgG1 antibody little is expected in milk and it is probably digested. US label: weigh benefits, allowing for the 2-month washout. LactMed: manufacturer advises no breastfeeding during treatment and for 2 months after. Do not breastfeed until 2 months after.
What does Zenocutuzumab interact with?
MediHelp does not list a checked interaction for Zenocutuzumab yet. Always tell your pharmacist about every medicine you take.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
